CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies
T cell-recruiting bispecific antibodies (bsAbs) are successfully used for the treatment of cancer. However, effective treatment with bsAbs is so far hampered by severe side effects, i.e., potentially life-threatening cytokine release syndrome. Off-target T cell activation due to binding of bispecifi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 September 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 18, Pages: 1-14 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13184596 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13184596 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/18/4596 
|
| Verfasserangaben: | Joseph Kauer, Fabian Vogt, Ilona Hagelstein, Sebastian Hörner, Melanie Märklin, Stefanie Maurer, Helmut R. Salih, Gundram Jung and Latifa Zekri |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780075278 | ||
| 003 | DE-627 | ||
| 005 | 20220820084608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211202s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13184596 |2 doi | |
| 035 | |a (DE-627)1780075278 | ||
| 035 | |a (DE-599)KXP1780075278 | ||
| 035 | |a (OCoLC)1341423981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kauer, Joseph |d 1992- |e VerfasserIn |0 (DE-588)1161466134 |0 (DE-627)102475524X |0 (DE-576)50654382X |4 aut | |
| 245 | 1 | 0 | |a CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies |c Joseph Kauer, Fabian Vogt, Ilona Hagelstein, Sebastian Hörner, Melanie Märklin, Stefanie Maurer, Helmut R. Salih, Gundram Jung and Latifa Zekri |
| 264 | 1 | |c 13 September 2021 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.12.2021 | ||
| 500 | |a This article belongs to the special issue "Cancer immunotherapy and immune-related adverse events" | ||
| 520 | |a T cell-recruiting bispecific antibodies (bsAbs) are successfully used for the treatment of cancer. However, effective treatment with bsAbs is so far hampered by severe side effects, i.e., potentially life-threatening cytokine release syndrome. Off-target T cell activation due to binding of bispecific CD3 antibodies to T cells in the absence of target cells may contribute to excessive cytokine release. We report here, in an in vitro setting, that off-target T cell activation is induced by bsAbs with high CD3 binding affinity and increased by endothelial- or lymphoid cells that act as stimulating bystander cells. Blocking antibodies directed against the adhesion molecules CD18/CD54 or CD2/CD58 markedly reduced this type of off-target T cell activation. CD18 blockade—in contrast to CD2—did not affect the therapeutic activity of various bsAbs. Since CD18 antibodies have been shown to be safely applicable in patients, blockade of this integrin holds promise as a potential target for the prevention of unwanted off-target T cell activation and allows the application of truly effective bsAb doses. | ||
| 650 | 4 | |a bispecific antibodies | |
| 650 | 4 | |a CD18 | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a T cell activation | |
| 700 | 1 | |a Vogt, Fabian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hagelstein, Ilona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hörner, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Märklin, Melanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maurer, Stefanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salih, Helmut R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jung, Gundram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zekri, Latifa |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 18, special issue, Artikel-ID 4596, Seite 1-14 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:18 |g supplement:special issue |g elocationid:4596 |g pages:1-14 |g extent:14 |a CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13184596 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/18/4596 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211202 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1161466134 |a Kauer, Joseph |m 1161466134:Kauer, Joseph |d 910000 |d 910100 |e 910000PK1161466134 |e 910100PK1161466134 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1780075278 |e 4012416855 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.3390/cancers13184596"],"eki":["1780075278"]},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"13 September 2021"}],"name":{"displayForm":["Joseph Kauer, Fabian Vogt, Ilona Hagelstein, Sebastian Hörner, Melanie Märklin, Stefanie Maurer, Helmut R. Salih, Gundram Jung and Latifa Zekri"]},"relHost":[{"title":[{"title":"Cancers","title_sort":"Cancers"}],"pubHistory":["1.2009 -"],"part":{"extent":"14","volume":"13","text":"13(2021), 18, special issue, Artikel-ID 4596, Seite 1-14","pages":"1-14","issue":"18","year":"2021"},"note":["Gesehen am 27.05.2020"],"disp":"CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodiesCancers","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"614095670","language":["eng"],"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisher":"MDPI"}],"id":{"eki":["614095670"],"zdb":["2527080-1"],"issn":["2072-6694"]},"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"14 S."}],"title":[{"title_sort":"CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies","title":"CD18 antibody application blocks unwanted off-target T cell activation caused by bispecific antibodies"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Kauer, Joseph","given":"Joseph","family":"Kauer"},{"role":"aut","display":"Vogt, Fabian","roleDisplay":"VerfasserIn","given":"Fabian","family":"Vogt"},{"display":"Hagelstein, Ilona","roleDisplay":"VerfasserIn","role":"aut","family":"Hagelstein","given":"Ilona"},{"role":"aut","display":"Hörner, Sebastian","roleDisplay":"VerfasserIn","given":"Sebastian","family":"Hörner"},{"role":"aut","display":"Märklin, Melanie","roleDisplay":"VerfasserIn","given":"Melanie","family":"Märklin"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Maurer, Stefanie","given":"Stefanie","family":"Maurer"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Salih, Helmut R.","given":"Helmut R.","family":"Salih"},{"role":"aut","display":"Jung, Gundram","roleDisplay":"VerfasserIn","given":"Gundram","family":"Jung"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Zekri, Latifa","given":"Latifa","family":"Zekri"}],"language":["eng"],"recId":"1780075278","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 02.12.2021","This article belongs to the special issue \"Cancer immunotherapy and immune-related adverse events\""]} | ||
| SRT | |a KAUERJOSEPCD18ANTIBO1320 | ||